Flupentixol

NERVOUS SYSTEM

Key facts

Flupentixol is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1964. DrugCentral lists 16 molecular targets, including Drd1, HRH1 and DRD3. Recorded indications include Schizophrenia.

• Molecular targets: Drd1, HRH1, DRD3 and DRD2 (16 listed in DrugCentral).
• Indications: Schizophrenia.
• ATC code: N05AF01 (Thioxanthene derivatives).
• Molecular formula: C23H25F3N2OS; molecular weight 434.52 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Schizophrenia

Mechanism & targets

Molecular targets (16)

Target	Gene	Action	Activity
D(1A) dopamine receptor	Drd1	unknown	IC50 9.52
Histamine H1 receptor	HRH1	unknown	Ki 9.07
D(3) dopamine receptor	DRD3	antagonist	Ki 8.96
D(2) dopamine receptor	DRD2	antagonist	Ki 8.82
D(4) dopamine receptor	DRD4	unknown	Ki 8.80
Sigma non-opioid intracellular receptor 1	SIGMAR1	unknown	IC50 8.65
Dopamine receptor	Drd1|Drd3|Drd5|Drd4|Drd2	unknown	IC50 8.52
D(1A) dopamine receptor	DRD1	antagonist	Ki 8.40
D(1B) dopamine receptor	DRD5	antagonist	Ki 8.10
D(1A) dopamine receptor	DRD1	unknown	Ki 7.75
5-hydroxytryptamine receptor 2A	HTR2A	unknown	Ki 7.06
Histone deacetylase 6	HDAC6	unknown	IC50 5.81
Potassium channel subfamily K member 2	KCNK2	unknown	IC50 5.70
5-hydroxytryptamine receptor 1A	HTR1A	unknown	Ki 5.09
Solute carrier family 22 member 1	SLC22A1	unknown	IC50 4.05
Alpha-1A adrenergic receptor	ADRA1A	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1964-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
N05AF01	NERVOUS SYSTEM › PSYCHOLEPTICS › ANTIPSYCHOTICS › Thioxanthene derivatives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Blood prolactin abnormal	1568.3
Anosognosia	1562.6
Disturbance in social behaviour	1474.7
Sexual dysfunction	1312.1
Suicide attempt	1301.4
Metabolic disorder	1257.9
Personality change	1180.3
Dyskinesia	980.7
Dystonia	975.2
Sedation	864.0
Antipsychotic drug level below therapeutic	732.4
Disinhibition	685.0

Chemical structure

• Molecular formula: C₂₃H₂₅F₃N₂OS
• Molecular weight: 434.52 g/mol
• CAS number: 2709-56-0
• InChIKey: NJMYODHXAKYRHW-UHFFFAOYSA-N
• PubChem CID: 5281881

OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Flupentixol used for?

DrugCentral lists the following indications for Flupentixol: Schizophrenia.

How does Flupentixol work?

Its molecular targets in DrugCentral include Drd1, HRH1, DRD3 (antagonist) and DRD2 (antagonist).

When was Flupentixol first approved?

Flupentixol was first approved by the YEAR INTRODUCED in 1964.

What is the chemical formula of Flupentixol?

Flupentixol has the molecular formula C23H25F3N2OS and a molecular weight of 434.52 g/mol.

Sources

• DrugCentral drug card 1211 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL6066864 — compound record and bioactivity
• PubChem CID 5281881 — chemical identifiers
• DrugBank DB00875 — drug record
• FDA UNII 21HMQ851IS — substance identity
• UniProt P35367 (HRH1) — target protein
• UniProt P35462 (DRD3) — target protein
• UniProt P14416 (DRD2) — target protein
• UniProt P21917 (DRD4) — target protein
• UniProt Q99720 (SIGMAR1) — target protein
• UniProt P21728 (DRD1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.